Astria Therapeutics Inc. (ATXS)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Astria Therapeutics, Inc. (ATXS) Reports Q3 Loss, Misses Revenue Estimates
Astria Therapeutics, Inc. (ATXS) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.42 per share a year ago.
All You Need to Know About Astria Therapeutics (ATXS) Rating Upgrade to Buy
Astria Therapeutics (ATXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Astria Therapeutics, Inc. (ATXS) Presents at Cantor Global Healthcare Conference 2025 Transcript
Astria Therapeutics, Inc. (NASDAQ:ATXS ) Cantor Global Healthcare Conference 2025 September 4, 2025 3:20 PM EDT Company Participants Jill Milne - Co-Founder, CEO, President & Director Conference Call Participants Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Presentation Steven Seedhouse MD & Biotechnology Analyst Okay. Great. Good afternoon, everyone, and welcome to the next session at the Cantor Global Healthcare Conference.
Astria Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 115 | $671.03 | $1,446.7 | $775.67 | 115.59% |
 David Jarvis Corton Capital Inc. | 21,369 | $155,566.32 | $268,822.02 | $113,255.7 | 72.8% |
| VT Vincent Tortorella Point72 (DIFC) Ltd | 2,319 | $16,881 | $29,173.02 | $12,292.02 | 72.82% |
Astria Therapeutics Inc. (ATXS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Astria Therapeutics Inc. ever had a stock split?
Astria Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jill C. Milne CEO | NASDAQ (NMS) Exchange | 04635X102 CUSIP |
| US Country | 78 Employees | - Last Dividend | 20 Aug 2021 Last Split | - IPO Date |
Overview
Astria Therapeutics, Inc. is a focused biopharmaceutical entity dedicated to the advancement and commercialization of novel treatments tailored for the management of allergic and immunological maladies within the United States. The entity traces its origins to 2008, initially established as Catabasis Pharmaceuticals, Inc., before rebranding to its current identity in September 2021. Headquartered in the bustling hub of Boston, Massachusetts, Astria Therapeutics is at the forefront of developing therapeutic solutions designed to address complex diseases with an immune or allergic component, leveraging cutting-edge scientific research and clinical development strategies.
Products and Services
-
STAR-0215
This leading product candidate emerges as a monoclonal antibody engineered to inhibit plasma kallikrein. It is currently navigating the stages of Phase 1b/2 clinical trials, aiming to offer a groundbreaking treatment for hereditary angioedema. Hereditary angioedema is characterized by spontaneous, severe swelling in various parts of the body, including the extremities, face, gastrointestinal tract, and airways, posing potentially life-threatening complications. The development of STAR-0215 represents Astria Therapeutics' commitment to addressing the unmet needs within the hereditary angioedema patient community through innovative therapeutic approaches.
-
STAR-0310
Still in the preclinical development phase, STAR-0310 is a monoclonal antibody specifically acting as an OX40 antagonist. Its therapeutic target is atopic dermatitis, an immune disorder marked by a compromised skin barrier function that leads to severe itching and discomfort. By focusing on the underlying immune responses contributing to the pathology of atopic dermatitis, STAR-0310 positions itself as a potential candidate for effectively managing and treating this distressing skin condition. Astria Therapeutics' endeavor to develop STAR-0310 underscores its broader objective to expand its portfolio with innovative solutions for immunological diseases beyond hereditary angioedema.
